{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T01:13:32Z","timestamp":1760404412736,"version":"3.38.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.euroneuro.2010.12.004","type":"journal-article","created":{"date-parts":[[2011,1,29]],"date-time":"2011-01-29T09:30:08Z","timestamp":1296293408000},"page":"526-531","source":"Crossref","is-referenced-by-count":12,"title":["The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats"],"prefix":"10.1016","volume":"21","author":[{"given":"Elizabeth N.","family":"Holly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bree","family":"Ebrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Prus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2010.12.004_bb0005","doi-asserted-by":"crossref","first-page":"12157","DOI":"10.1073\/pnas.94.22.12157","article-title":"Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice","volume":"94","author":"Adams","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0010","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/0091-3057(86)90203-0","article-title":"Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission","volume":"24","author":"Ahlenius","year":"1986","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0015","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0028-3908(96)00110-4","article-title":"5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential","volume":"35","author":"Bartoszyk","year":"1996","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0020","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0031-6997(24)01509-6","article-title":"Neurotensin and dopamine interactions","volume":"53","author":"Binder","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0014-2999(01)01197-9","article-title":"A novel neurotensin analog blocks cocaine- and d-amphetamine-induced hyperactivity","volume":"426","author":"Boules","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.brainres.2009.10.050","article-title":"NT79: a novel neurotensin analog with selective behavioral effects","volume":"1308","author":"Boules","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0006-8993(99)02363-X","article-title":"Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol","volume":"856","author":"Cusack","year":"2000","journal-title":"Brain Res"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0304-3940(86)90149-7","article-title":"Repeated neurotensin administration in the ventral tegmental area: effects on baseline and d-amphetamine-induced locomotor activity","volume":"68","author":"Elliott","year":"1986","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0045","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0022-3565(24)38010-3","article-title":"Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist","volume":"288","author":"Feifel","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0050","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.npp.1300083","article-title":"A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist","volume":"28","author":"Feifel","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0055","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.npp.1300378","article-title":"Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects","volume":"29","author":"Feifel","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0060","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00213-008-1197-5","article-title":"The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance","volume":"200","author":"Feifel","year":"2008","journal-title":"Psychopharmacolog Berl"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0065","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/npp.2009.15","article-title":"The Brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog","volume":"34","author":"Feifel","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0070","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuropharm.2009.07.001","article-title":"The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature","volume":"58","author":"Feifel","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10401230209147398","article-title":"Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria","volume":"14","author":"Gerlach","year":"2002","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1017\/S1461145700002042","article-title":"The new generation of antipsychotic drugs: how atypical are they?","volume":"3","author":"Goldstein","year":"2000","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0085","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.neuropharm.2005.06.010","article-title":"Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8\u201313) analogues containing non-natural arginine and lysine residues","volume":"49","author":"Hadden","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1126\/science.286.5437.105","article-title":"Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade","volume":"286","author":"Hertel","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0014-2999(01)01076-7","article-title":"Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity","volume":"422","author":"Hertel","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-2999(02)01414-0","article-title":"Repeated administration of the neurotensin analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour","volume":"439","author":"Hertel","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0105","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/FBP.0b013e32833e7efd","article-title":"Evaluation of the effects of alpha2 adrenoceptor antagonism with the D2 receptor antagonist raclopride on conditioned avoidance responding in rats","volume":"21","author":"Jacobson","year":"2010","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0110","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0301-0082(97)00025-7","article-title":"Neurotensin and the serotonergic system","volume":"52","author":"Jolas","year":"1997","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0006-8993(82)90566-2","article-title":"The effects of neuropeptides on discrete-trial conditioned avoidance responding","volume":"237","author":"Luttinger","year":"1982","journal-title":"Brain Res"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0120","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1016\/j.peptides.2006.01.028","article-title":"Neurotensin and growth of normal and neoplastic tissues","volume":"27","author":"Mark Evers","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0125","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0022-3565(24)37732-8","article-title":"S 16924 ((R)-2-{1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol","volume":"286","author":"Millan","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0130","unstructured":"National Research Council (1996) Guide for laboratory animal facilities and care. National Research Council, National Research Council"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0135","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pbb.2006.05.006","article-title":"Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats","volume":"84","author":"Olsen","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0140","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/sj.npp.1300494","article-title":"The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat","volume":"29","author":"Petrie","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0145","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0196-9781(97)00145-9","article-title":"Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist","volume":"18","author":"Sarhan","year":"1997","journal-title":"Peptides"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0150","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/BF00518179","article-title":"Possible neuronal mechanisms involved in neurotensin-induced catalepsy in mice","volume":"91","author":"Shibata","year":"1987","journal-title":"Psychopharmacolog Berl"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0155","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.pbb.2008.05.025","article-title":"The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle","volume":"90","author":"Shilling","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0160","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0166-4328(03)00037-8","article-title":"The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition","volume":"143","author":"Shilling","year":"2003","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0165","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00213-004-1835-5","article-title":"Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an alpha1 agonist","volume":"175","author":"Shilling","year":"2004","journal-title":"Psychopharmacolog Berl"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0170","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0028-3908(82)90032-6","article-title":"Neurotensin induces catalepsy in mice","volume":"21","author":"Snijders","year":"1982","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0175","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0149-7634(99)00037-8","article-title":"The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?","volume":"23","author":"Wadenberg","year":"1999","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1056-8719(97)00104-4","article-title":"A novel computer-controlled conditioned avoidance apparatus for rats","volume":"38","author":"Wadenberg","year":"1998","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0091-3057(00)00483-4","article-title":"Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats","volume":"68","author":"Wadenberg","year":"2001","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.euroneuro.2010.12.004_bb0190","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/0960-894X(95)00155-M","article-title":"Reduced amide bond neurotensin 8\u201313 mimetics with potent in vivo activity","volume":"5","author":"Wustrow","year":"1995","journal-title":"Bioorg Med Chem Lett"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X10002804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X10002804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T07:30:25Z","timestamp":1740900625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X10002804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0924977X10002804"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2010.12.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"type":"print","value":"0924-977X"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}